menu
    • menu

    Company profile for Autolus Therapeutics

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Autolus is a biopharmaceutical company. It is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Since its inception, the company has undergone rapid growth, systematically adding the capabilities needed to manufacture and develop its programmed T cell product candidates. Autolus is committed to bringing life-changing treatments to cancer patient...
    Autolus is a biopharmaceutical company. It is founded on advanced cell programming technology pioneered by Dr Martin Pule and was spun-out from University College London in 2014. Since its inception, the company has undergone rapid growth, systematically adding the capabilities needed to manufacture and develop its programmed T cell product candidates. Autolus is committed to bringing life-changing treatments to cancer patients by reprogramming their own T-cells to combat the treatment of haematological malignancies and solid tumours.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Autolus Therapeuticsunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Forest House, 58 Wood Lane White City, London, W12 7RZ
    Telephone
    Telephone
    +44 (0)20 3829 6230
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.autolus.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Innovative Therapeutics Pipeline Boosts Industry Market Growth
    Innovative Therapeutics Pipeline Boosts Industry Market Growth

    15 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/innovative-therapeutics-pipeline-positions-industry-for-strong-market-growth-302555530.html

    PR NEWSWIRE
    15 Sep 2025
    Share Share
    AGC Biologics To Produce LVV For FDA-Approved CAR-T Aucatzyl
    AGC Biologics To Produce LVV For FDA-Approved CAR-T Aucatzyl

    12 Dec 2024

    // ACCESSWIRE

    https://www.accesswire.com/954185/agc-biologics-to-manufacture-lvv-for-car-t-therapy-approved-by-fda-for-autolus-therapeutics-aucatzyl

    ACCESSWIRE
    12 Dec 2024
    Share Share
    FDA approves Autolus’ CAR-T cell therapy for aggressive blood cancer
    FDA approves Autolus’ CAR-T cell therapy for aggressive blood cancer

    12 Nov 2024

    // ENDPTS

    https://endpts.com/fda-approves-autolus-car-t-cell-therapy-for-aggressive-blood-cancer/

    ENDPTS
    12 Nov 2024
    Share Share
    BioNTech pays Autolus $250M to use manufacturing, CAR-T tech
    BioNTech pays Autolus $250M to use manufacturing, CAR-T tech

    08 Feb 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/biontech-pays-autolus-250m-manufacturing-car-t-expertise-wide-ranging-collab

    FIERCE BIOTECH
    08 Feb 2024
    Share Share
    Autolus eyes November for potential US approval of Tecartus rival
    Autolus eyes November for potential US approval of Tecartus rival

    22 Jan 2024

    // ENDPTS

    https://endpts.com/autolus-eyes-november-for-potential-us-approval-of-tecartus-rival/

    ENDPTS
    22 Jan 2024
    Share Share
    Biotech CAR-T roundup: Autolus, Gracell tout early-stage data at #ASH23
    Biotech CAR-T roundup: Autolus, Gracell tout early-stage data at #ASH23

    12 Dec 2023

    // Max Gelman ENDPTS

    https://endpts.com/biotech-car-t-roundup-autolus-gracell-tout-early-stage-data-at-ash/

    Max Gelman ENDPTS
    12 Dec 2023
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search